New Health and Mounjaro

15 October 2026

MedPal AI plc

("MedPal", the "Company" or the "Group")

New Health enters the top 30 UK Mounjaro providers in three months

Ranked 29th by Eli Lilly, with over 42,500 customers and 2.1% GLP-1 market share

Eli Lilly, the exclusive supplier of GLP-1 Mounjaro, has confirmed that New Health has risen from 3,048th to 29th place in its supplier list (by volume supplied). This has taken approximately three months since the Company's initial marketing campaign began.

Novo Nordisk, in written evidence to the House of Commons Health and Social Care Committee in August 2025, estimated that approximately 2 million people in the UK were using GLP-1 medicines for weight management, over 90 per cent. of them privately. New Health now has over 42,500 customers, representing approximately 2.1 per cent. of this market, up from more than 33,000 as at 30 September 2026

On the basis of Eli Lilly's ranking, the Directors consider New Health to be among the fastest growing GLP-1 providers in the UK and the Group remains on track to open its expanded GLP-1 line at Sarus Court by the end of October 2026, taking capacity to 14,000 orders a day.

Jason Drummond, Founder and Chief Executive Officer, commented:

"From 3,048th to 29th in three months. Eli Lilly's own ranking confirms the scale of what New Health has built since July. We now have more than 42,500 customers, representing approximately two per cent. of the UK's GLP-1 users.

"Two weeks ago we said repeat orders would grow as customers reached their first reorder date. They now make up over 30 per cent. of New Health revenue, up from 22 per cent. in September, with no acquisition cost attached. Our ambition is to be a top three UK GLP-1 provider. The expanded line at Sarus Court opens this month with capacity for 14,000 orders a day. This is what the Health OS was built for, and it is only the beginning."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries

MedPal AI plc - Jason Drummond, Chief Executive Officer: via Square1 Consulting

Cairn Financial Advisers LLP (Nomad) - Louise O'Driscoll / Jo Turner: +44 (0) 20 7213 0880

Merlin Partners LLP (formerly Oak Securities) - +44 (0) 20 7839 3500

Clear Capital Markets Limited - Bob Roberts: +44 (0) 20 3869 6080

Square1 Consulting - David Bick: +44 (0) 20 7929 5599 / +44 (0) 7831 381201

About MedPal AI plc

MedPal AI plc (AIM: MPAL; FRA: Z1N) is a vertically integrated, AI-native digital health and pharmacy group. The Group operates NHS Distance Selling Pharmacy hubs at Sarus Court, Runcorn and Swaffham, New Health (new.co.uk), a dedicated GLP-1 weight management clinic, a B2B care home pharmacy supply business, eMARx, the Group's electronic medication administration record software for care homes, and Juno, an agentic AI health companion built on Anthropic's Claude. MedPal's ambition is to build the UK's leading Health OS: a single platform connecting prescribing, dispensing, delivery, administration and AI-driven patient support. The Company's LEI is 984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These statements, including statements regarding the Group's market position, the opening of additional capacity and trading in October 2026, are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Third party market estimates referred to in this announcement have not been independently verified by the Company. No statement in this announcement is intended to be a profit forecast. The Company undertakes no obligation to update any forward-looking statements except as required by law or the AIM Rules for Companies.

END